首页> 美国卫生研究院文献>British Journal of Cancer >Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
【2h】

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.

机译:白细胞介素2和干扰素αA / D处理对荷瘤小鼠淋巴细胞的影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The in vivo antitumour activities of recombinant human interleukin-2 (rHIL-2) and recombinant human hybrid interferon alpha A/D (rIFN-alpha A/D) were tested in relation to adenocarcinoma 755. The tumour growth, following s.c. inoculation of tumour cells, was inhibited to a greater extent in mice treated with the combination of cytokines than in mice treated with either one alone. Pretreatment with these cytokines did not affect the tumour growth. Injection of tumour-bearing mice with a combination of these cytokines resulted in a marked increase in the total number of lymphocytes in the peritoneal cavity. Among them, Lyt-2+/L3T4- and asialo GM1+ cells were markedly enhanced by the combination of cytokines, and the frequencies of these marker cells were closely correlated with the antitumour activity. In tumour-bearing mice, the size of the thymus was decreased while that of the spleen was increased compared to non-tumour-bearing (normal) mice. Treatment with rHIL-2 caused the thymus, spleen and liver to be larger compared to untreated tumour-bearing mice, but when treated with a combination of rHIL-2 and rIFN-alpha A/D these organs were smaller than when rHIL-2 was administered alone. Thymocytes were drastically changed when mice were bearing a tumour or were treated with a cytokine. Especially immature T-cells, Lyt-2+/L3T4+, were drastically decreased in tumour-bearing mice, but were maintained following administration of rHIL-2 or rIFN-alpha A/D. When treated with rHIL-2 plus rIFN-alpha A/D, Lyt-2+/L3T4+ T-cells were decreased while Lyt-2+/L3T4- T-cells were increased. Frequency of immature T-cells, Lyt-2-/L3T4-, was not changed. On the other hand, T-cell subsets of splenocytes were markedly decreased in tumour-bearing mice compared to normal mice, but all the subsets of splenocytes were almost unchanged even when tumour-bearing mice were treated with rHIL-2 plus rIFN-alpha A/D. Thus, injection of rHIL-2 and rIFN-alpha A/D to tumour-bearing mice resulted in induction of Lyt-2+/L3T4- and asialo GM1+ cells in the peritoneal cavity, and the frequencies correlated with the observed antitumour activity in vivo in this murine model. The increase in Lyt-2+/L3T4- T-cells in the peritoneal cavity may be related to changes in the T-cells in thymus.
机译:测试了重组人白介素-2(rHIL-2)和重组人杂种干扰素αA / D(rIFN-αA / D)的体内抗肿瘤活性与腺癌755的关系。与单独使用任一细胞因子治疗的小鼠相比,在用细胞因子联合治疗的小鼠中肿瘤细胞的接种被更大程度地抑制。用这些细胞因子进行预处理不会影响肿瘤的生长。用这些细胞因子的组合注射给荷瘤小鼠导致腹膜腔中淋巴细胞总数的显着增加。其中,Lyt-2 + / L3T4-和去唾液酸GM1 +细胞通过细胞因子的结合而显着增强,并且这些标记细胞的频率与抗肿瘤活性密切相关。与非荷瘤(正常)小鼠相比,荷瘤小鼠的胸腺尺寸减小而脾脏尺寸增大。与未经治疗的荷瘤小鼠相比,使用rHIL-2处理可导致胸腺,脾脏和肝脏更大,但是当使用rHIL-2和rIFN-αA / D组合治疗时,这些器官比rHIL-2较小。单独服用。当小鼠患有肿瘤或接受细胞因子治疗时,胸腺细胞发生了巨大变化。特别是未成熟的T细胞,Lyt-2 + / L3T4 +,在荷瘤小鼠中显着减少,但在给予rHIL-2或rIFN-αA / D后得以维持。当用rHIL-2加rIFN-αA / D处理时,Lyt-2 + / L3T4 + T细胞减少,而Lyt-2 + / L3T4-T细胞增加。未成熟的T细胞Lyt-2- / L3T4-的频率未改变。另一方面,与正常小鼠相比,荷瘤小鼠脾细胞的T细胞亚群明显减少,但是即使用rHIL-2加rIFN-αA治疗荷瘤小鼠,脾细胞的所有亚群也几乎没有变化。 / D。因此,向荷瘤小鼠注射rHIL-2和rIFN-αA / D导致腹膜腔中诱导Lyt-2 + / L3T4-和无唾液酸GM1 +细胞,并且频率与体内观察到的抗肿瘤活性相关在这种鼠模型中腹膜腔中Lyt-2 + / L3T4- T细胞的增加可能与胸腺中T细胞的变化有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号